EGFR and cancer: The present study has demonstrated for the first time that breast cancer cell invasion can be enhanced by the ability of TNK2 to maintain EGFR cell surface expression and may provide the impetus for exploration of TNK2 as an alternative drug target for the treatment of EGFR-dependent cancers.